Navigation Links
Genesis Biopharma to Hold Business Update Conference Call on June 29

LOS ANGELES, June 22, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced that it will hold a conference call with the investment community on Wednesday, June 29, 2011 at Noon Eastern (9:00 a.m. Pacific).  The Company's Chairman and Chief Executive Officer, Anthony J. Cataldo, will provide an update on the business, and discuss the clinical and commercial development plans for the Company's new autologous cell therapy product candidate, Contego™, for the treatment of Stage IV metastatic melanoma.  There will also be a question and answer session following the presentation.

Individuals interested in listening to the conference call may do so by dialing 888-634-9408 for domestic callers, or 706-679-0879 for international callers, or from the webcast on the investor relations section of the Company's Web site at  A slide presentation will accompany the call and webcast, and will be available on the Company website.

A telephone replay will be available through July 1, 2011 by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers, and entering the Conference ID #: 78126182.  The webcast will be available on the Company's Web site for 60 days following the completion of the call.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit

Forward-Looking Statements

The foregoing announcement contains forward-looking statements that can be identified by such terminology as "expects", "hopes", "potential", "suggests", "bodes", "may", "should", "could", or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general.  Forward-looking statements speak only as of the date they are made.  The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ThermoGenesis Announces Webcast of Presentation at OnemedForum Conference
2. Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes
3. Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis
4. CryoLife Announces Completion of Acquisition of Cardiogenesis
5. CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
6. ThermoGenesis Reports Third Quarter Fiscal 2011 Results; Major Progress Achieved in China & India
7. Cardiogenesis Reports First Quarter 2011 Results
8. CryoLife Completes Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
9. ThermoGenesis Corp. to Announce Third Quarter Fiscal 2011 Results On May 5, 2011
10. Cardiogenesis Corporation to Report 2011 First Quarter Results on May 4th
11. CryoLife Announces Expiration of Go-Shop Period Related to its Proposed Acquisition of Cardiogenesis Corporation
Post Your Comments:
(Date:12/1/2015)... Va. , Dec. 1, 2015  AccuTEC ... unveiled a new corporate logo and brand identity ... the design and engineering of bladed products where ... --> --> Serving manufacturers ... glass, and auto glass equipment, AccuTEC,s product lines ...
(Date:12/1/2015)... months of adjunctive metformin therapy does not improve glycemic outcomes ... research from T1D Exchange and funded by the ... on measures of obesity, including weight and BMI. The results, ... the American Medical Association , are from the largest clinical ... and obese adolescents with type 1 diabetes. ...
(Date:12/1/2015)... N.J. , Dec. 1, 2015 ... held in San Francisco, CA ... solutions to the coronary marketplace. During a satellite ... in Stent Design to Minimize Restenosis", a renowned ... currently available Medinol NIRxcell™ CoCr Coronary Stent System ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... For the millions of people who use ... launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. “Hollister Continence Care ... portfolio,” said Michael Gresavage, Vice President North America. "We designed our VaPro Plus ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , ... control over customization, the possibilities are truly endless, all with a click of a ... position, vertical flip, horizontal flip, depth of field and more, all within Final Cut ...
(Date:11/30/2015)... ... November 30, 2015 , ... Third ... today that it has officially launched a sleek, mobile-ready and user-centric redesigned website. ... company’s new website clearly outlines the benefits that its SEO services provide to ...
(Date:11/30/2015)... ... , ... The National Association of Professional Women (NAPW) honors ... Circle. She is recognized with this prestigious distinction for leadership in estate sales and ... than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to welcome ...
Breaking Medicine News(10 mins):